AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12 déc. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons
10 déc. 2024 10h02 HE
|
Association of American Physicians and Surgeons
Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
09 déc. 2024 04h00 HE
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06 déc. 2024 09h15 HE
|
AIM ImmunoTech Inc.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
15 nov. 2024 07h51 HE
|
InflaRx N.V.
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
28 oct. 2024 08h05 HE
|
BlueWillow Biologics
ANN ARBOR, Mich., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will...
Fraser Institute News Release: Job growth in government exceeded the private sector in 8 out of 10 provinces from 2019-23
22 oct. 2024 05h00 HE
|
Fraser Institute
VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- In eight of 10 provinces the rate of government job growth has been higher than the private sector, finds a new study published today...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union
20 sept. 2024 08h10 HE
|
BioNTech SE
Der an Omikron KP.2 angepasste COVID-19-Impfstoff wird nach Zulassung durch die Europäische Kommission für Personen ab 6 Monaten verfügbar seinDaten zeigten, dass der an Omikron KP.2 angepasste...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
20 sept. 2024 08h10 HE
|
BioNTech SE
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron...
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
04 sept. 2024 09h15 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for...